The kallikrein-kinin pathways in hypertension and diabetes.

摘要: Cardiovascular diseases are the most common causes of mortality worldwide. Hypertension and diabetes two major risk factors in development cardiac hypertrophy, ischemic heart disease, failure. In Kuwait, high rate prevalence hypertension has been documented. Previous studies have indicated altered activities BK-generating components diabetes. Bradykinin is pharmacologically active polypeptide that can promote both cardiovascular renal function, for example, vasodilation, natriuresis, diuresis, release nitric oxide (NO). addition, B2 kinin receptors present endothelial cells which may enhance biosynthesis NO. It demonstrated reduced urinary (renal) kallikrein levels be associated with blood pressure humans spontaneously hypertensive diabetic rats. The BK produce its pharmacological effects via NO cyclic GMP release. Furthermore, it established cardioprotective actions myocardial ischemia prevent left ventricular hypertrophy. Also, transgenic mice carrying tissue gene overexpressing had pressure. synthase involved regulation. ability delivery use receptor agonists to a wide spectrum beneficial make powerful candidate treating hypertension, cardiovascular, diseases. Strategies activate might applicable treatment disease. Increased plasma prekallikrein patients serve as an indicator developing damage. Also urine concentrations cause higher glucose blood.